Here’s our fortnightly wrap of all the news driving ASX health stocks.

It’s been a pretty dismal two weeks for ASX healthcare stocks, with 90 of the 134 small-cap companies we track in the sector losing ground and just 33 gaining it. Another 10 companies were flat while the last just joined the ASX yesterday.

Taking a longer view, 67 companies of these companies are up so far in 2021, while 57 are down.

Code Company Price % return since Feb 17 %YTD return % return since 31/12/19 MktCap
SHG Singular Health 63 40.0 $29,474,550
RAC Race Oncology 391 31.6 123.4 1084.8 $495,293,623
AMT Allegra Orthopaedics 36.5 21.7 4.3 247.6 $36,038,425
RSH Respiri 14.5 3.6 11.5 95.9 $97,516,007
NC6 Nanollose 10 -20.0 85.2 140.3 $13,106,400
CAJ Capitol Health 34.5 21.1 25.5 22.4 $349,332,154
CGS Cogstate 101.5 -1.0 -7.7 174.3 $169,387,139
NSB Neuroscientific 23.5 0.0 -6.0 67.9 $22,194,844
PYC PYC Therapeutics 14.5 11.5 -1.7 143.5 $459,784,285
ACW Actinogen Medical 2.3 0.0 9.5 -9.7 $35,468,317
RNO Rhinomed 13.5 17.4 -15.6 -10.0 $31,726,142
JHC Japara Healthcare Lt 84 7.7 35.5 -6.5 $239,186,359
RHY Rhythm Biosciences 152.5 10.5 74.3 2255.2 $313,442,611
BWX BWX 430 10.5 4.6 13.6 $612,598,151
SVA Simavita 1.7 -5.6 6.3 -15.0 $23,671,965
ALC Alcidion Group 26 20.9 40.5 73.3 $257,580,454
MX1 Micro-X 41 15.5 15.5 153.3 $188,375,213
TD1 Tali Digital 4.9 4.3 4.3 113.0 $42,771,893
RGS Regeneus 12.5 13.6 0.0 78.6 $34,532,704
ICR Intelicare Holdings 27 3.8 12.5 $9,520,488
CDY Cellmid 9.2 -6.1 -16.4 -38.7 $11,576,320
TRU Truscreen 9.6 1.1 $32,657,963
EYE Nova EYE Medical 33.5 -4.3 -5.6 -3.3 $47,416,426
PNV Polynovo 245 -2.0 -36.9 -2.4 $1,627,014,588
ICS ICSGlobal 201 5.2 -4.7 -12.5 $21,153,278
4DX 4Dmedical 173 -11.3 -28.8 $307,057,831
TLX Telix Pharmaceutical 400 -4.1 5.8 197.4 $1,130,033,448
EZZ EZZ Life Science 116 $6,000,000
ALT Analytica 0.3 0.0 0.0 50.0 $8,799,031
SDI SDI 79.5 4.6 1.3 -12.5 $95,092,424
OVN Oventus Medical 21 0.0 -10.6 -61.1 $33,235,108
JHL Jayex Healthcare 4.6 -8.0 17.9 142.1 $9,665,425
RAP Resapp Health 5.9 -9.2 -30.6 -68.1 $43,970,930
APH AP Hemp 46 -6.1 35.3 240.7 $32,803,409
FFC Farmaforce 9.9 10.0 10.0 45.6 $12,937,417
ADR Adherium 1.8 -10.0 -35.7 -21.7 $13,591,920
AHK Ark Mines 3.4 0.0 0.0 0.0 $1,778,920
EPN Epsilon Healthcare 24.5 -2.0 4.3 -30.0 $42,627,814
CYP Cynata Therapeutics 65 -4.4 -5.1 -27.2 $93,129,786
CHM Chimeric Therapeutic 31 0.0 $63,862,500
1ST 1St Group 3.2 -3.0 -5.9 -17.9 $12,738,507
ONT 1300 Smiles 742 -6.9 10.3 26.3 $175,456,825
LBT LBT Innovations 9.9 -10.0 -19.2 -19.2 $27,755,056
UBI Universal Biosensors 42.5 1.2 -2.3 183.3 $76,337,987
GSS Genetic Signatures 164 -6.8 -18.4 47.1 $242,172,694
MDR Medadvisor 37 2.8 4.2 -2.5 $125,817,008
M7T Mach7 Tech 141.5 -6.9 13.2 114.0 $345,456,444
HCT Holista CollTech 7.1 -1.4 -1.4 -58.2 $19,274,436
NEU Neuren Pharmaceut. 131 -4.0 1.9 -31.9 $148,990,540
PBP Probiotec 220 -3.9 -7.5 8.7 $175,758,029
PAR Paradigm Bio. 246 -5.4 -3.5 -17.2 $514,948,369
ARX Aroa Biosurgery 121 -0.4 5.2 $366,886,225
AGH Althea Group 51.5 -3.7 18.4 66.1 $136,434,241
1AD Adalta 17 -10.5 36.0 122.9 $41,679,895
MVF Monash IVF Group 75.5 -1.9 -3.8 -9.4 $286,381,607
MEM Memphasys 10.5 -8.7 5.0 75.0 $74,457,840
SOM SomnoMed 177.25 -4.7 -15.6 -31.2 $148,966,767
OSX Osteopore 45 -4.3 -13.5 -10.0 $34,336,632
S66 Star Combo 29 5.5 -12.1 -43.1 $39,066,616
HXL Hexima 14 -6.7 -24.3 -54.1 $18,657,723
PGC Paragon Care 27 -3.6 20.0 14.9 $92,918,455
RCE Recce Pharmaceutical 103.5 -0.5 -1.9 172.4 $179,860,072
OPT Opthea 161.5 -10.0 -15.9 -50.6 $545,327,633
OIL Optiscan Imaging 22.5 21.6 114.3 837.5 $140,241,021
CYC Cyclopharm 253 -9.6 1.2 144.2 $239,039,547
OSL Oncosil Medical 10.5 -16.0 -12.5 -20.7 $84,771,046
IMU Imugene 10 -4.8 0.0 284.6 $475,959,931
MEB Medibio 0.9 -10.0 12.5 32.4 $14,128,963
NOX Noxopharm 69.5 -15.8 41.8 249.8 $197,826,973
PIQ Proteomics Int Lab 125 13.6 57.2 323.7 $131,319,844
AT1 Atomo Diagnostics 24.5 -14.0 -19.7 $99,933,133
MVP Medical Developments 550 -13.1 -17.7 -37.3 $400,507,457
VTI Vision Tech 1.9 0.0 -24.0 -44.1 $17,887,060
IVX Invion 0.9 -18.2 -10.0 0.0 $49,840,131
VLS Vita Life Sciences.. 91 -4.7 -9.0 45.8 $49,215,177
OSP Osprey Med Inc 1.8 -10.0 -18.2 5.9 $43,114,328
CAN Cann Group 62 -15.1 5.1 -33.0 $166,875,162
VBS Vectus Biosystems 125 -6.7 4.2 150.0 $39,569,243
ACR Acrux 17 -2.9 3.0 17.2 $49,407,663
BPH BPH Energy 16.5 -24.1 283.7 1802.5 $112,976,837
MDC Medlab Clinical 32 -1.5 33.3 28.0 $90,894,593
DVL Dorsavi 3.2 -9.9 -22.0 59.4 $11,545,003
DOC Doctor Care Anywhere 122 -2.8 1.7 $226,483,916
OCC Orthocell 51.5 -10.4 14.4 51.5 $96,284,316
PAA Pharmaust 9.8 -6.7 -6.7 8.9 $31,672,992
PXS Pharmaxis 8.2 -4.7 -11.8 -13.7 $32,573,171
BIT Biotron 6.9 -6.8 -11.5 -44.8 $47,731,424
PAB Patrys 2.6 0.0 8.3 74.5 $47,008,436
AHC Austco Healthcare 9 -8.2 -9.1 -5.3 $25,577,006
NYR Nyrada Inc. 31.5 -18.2 31.3 75.0 $24,481,728
KZA Kazia Therapeutics 132 6.5 13.8 125.8 $166,539,468
LSH Lifespot Health 12.5 4.2 62.3 290.2 $21,058,370
CMP Compumedics 42 -8.7 -16.0 -37.3 $74,408,438
BXN Bioxyne 1.2 0.0 0.0 0.0 $8,321,890
PSQ Pacific Smiles Grp 270 -0.7 5.9 53.9 $414,491,985
AVE Avecho Biotech 2.1 -16.0 -27.6 425.0 $40,235,683
ANP Antisense Therapeut. 16 -17.9 23.1 158.1 $103,330,069
GTG Genetic Technologies 1.2 0.0 60.0 50.0 $99,156,494
NXS Next Science 124 5.1 -0.8 -44.1 $151,692,003
ONE Oneview Healthcare 7.8 -12.4 73.3 -20.3 $32,578,570
DXB Dimerix 23.5 -20.3 0.0 51.6 $47,519,831
IDT IDT Australia 19 -9.5 2.7 40.7 $44,444,338
SCU Stemcell United 2.8 3.7 47.4 115.4 $22,688,658
SUD Suda Pharmaceuticals 4.5 -8.2 12.5 -8.4 $17,309,520
ZNO Zoono Group 69.5 -7.3 -47.1 -67.3 $112,417,204
BD1 Bard1 Life Sciences 292 -8.2 329.4 247.6 $224,474,653
BOT Botanix Pharma 11.5 -14.8 -8.0 51.3 $107,045,628
IMC Immuron 21 -16.0 -8.7 68.0 $47,721,785
IBX Imagion Biosys 17 -20.9 17.2 658.3 $179,704,732
LCT Living Cell Tech. 1.7 -19.0 21.4 0.0 $9,714,497
CDX Cardiex 7.6 -16.5 35.7 230.4 $76,722,474
CP1 Cannpal Animal 16.5 -8.3 -2.9 32.0 $14,900,000
CTE Cryosite 20 -4.8 -49.4 194.1 $9,371,913
MMJ MMJ Group Hlds 12 -11.1 -4.0 20.0 $28,744,248
PCK Painchek 8.1 11.0 5.2 -22.9 $86,763,970
ZLD Zelira Therapeutics 6.7 -16.3 -27.2 52.3 $80,941,962
CPH Creso Pharma 20.5 -10.9 13.9 135.6 $195,472,624
CBL Control Bionics 65 -11.0 -30.9 $31,574,768
ATH Alterity Therap 3.4 -20.9 9.7 161.5 $72,940,584
ATX Amplia Therapeutics 24 -15.8 0.0 241.4 $28,043,267
EXL Elixinol Global 19.5 -15.2 11.4 -52.4 $61,196,651
IMM Immutep 33.5 -20.2 -19.3 -14.1 $227,053,850
AC8 Auscann Grp Hlgs 15.5 -13.9 -20.5 -32.6 $49,142,340
NTI Neurotech Intl 7 6.1 55.6 900.0 $35,345,251
VHT Volpara Health Tech 130 -15.0 -9.4 -9.1 $331,345,187
IPD Impedimed 11 -24.1 -12.0 29.6 $150,629,403
PAL Palla Pharma 58.5 9.9 -24.0 -24.5 $75,568,786
PTX Prescient 9.1 -24.2 35.8 116.7 $60,211,983
IHL Incannex Healthcare 20 -16.7 29.0 300.0 $216,077,026
BNO Bionomics 32.5 16.1 124.1 589.6 $264,689,118
RHT Resonance Health 19 -2.6 -20.8 31.0 $85,234,376
GLH Global Health 36 -10.0 -23.4 176.9 $15,155,395
MXC Mgc Pharmaceuticals 8 15.9 220.0 196.3 $178,304,664
ADO Anteotech 19 -26.9 81.0 978.0 $383,380,074

AnteoTech (ASX:ADO) has been the biggest loser over the fortnight, falling 26.9 per cent to 19c. But given that diagnostic testing company is still up 81 per cent for the year and nearly 11-fold in the past 12 months, we don’t imagine long-term shareholders are complaining too much.

Meanwhile, the best performer from February 17 to March 3 was medtech Singular Health (ASX:SHG), which only joined the ASX on February 12. SHG shares gained 40 per cent over the two weeks to finish yesterday at 63c.

The medical imaging company raised $6 million at 20 cents per share under the IPO offer, meaning investors like Bhavdip Sanghavi (well known as @Bhavdip143 on Twitter) have more than tripled their money in a short period of time.


 

Race Oncology

Race Oncology (ASX:RAC) was the second-best performer, with its shares up 31.6 per cent in the two weeks from February 17 to March 3. They gained 4.6 per cent yesterday to close at $3.91, its best-ever finish. RAC shares in the afternoon changed hands at $3.98, equalling an intraday all-time high set on Tuesday.

The company has been riding a wave of positive sentiment since its announcement on February 23 that pre-clinical data from the University of Newcastle indicates its small molecule anti-cancer drug, Bisantrene, could be an effective chemotherapeutic agent against ovarian cancer.

The precision oncology company is the fifth-best performer on our list so far in 2021, having gained 123 per cent, and the third-best gainer in the last 12 months, with a 1,085 per cent rise.

Allegra Orthopaedics (ASX:AMT) was up 21.7 per cent over the fortnight, to 36.5c, following progress on its spinal cage, a 3D-printable synthetic device that aims to regenerate bone and be completely absorbed by the body.

The fourth-best gainer is OptiScan Imaging (ASX:OIL), which advanced 21.6 per cent over the two weeks after announcing February 25 that its revenue for the half-year ended December 31 was up 60.4 per cent to $533,574.

The endoscope manufacturer’s loss was up as well, however, by 37.5 per cent to $751,715.

Shareholders obviously see potential, with OIL shares up 114 per cent year-to-date and by 834 per cent in the past 12 months.